Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
39
TBPH Quote, Financials, Valuation and Earnings
Last price:
$11.61
Seasonality move
:
-3.18%
Day range:
$11.46 - $11.68
52-week range:
$7.44 - $11.82
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.78x
P/B ratio:
3.51x
Volume:
199.5K
Avg. volume:
244.5K
1-year change:
16.62%
Market cap:
$582.5M
Revenue:
$64.4M
EPS (TTM):
-$1.18
Analysts' Opinion
-
Consensus RatingTheravance Biopharma has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $17.20, Theravance Biopharma has an estimated upside of 47.64% from its current price of $11.65.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $11.65.
Fair Value
-
According to the consensus of 4 analysts, Theravance Biopharma has 47.64% upside to fair value with a price target of $17.20 per share.
TBPH vs. S&P 500
-
Over the past 5 trading days, Theravance Biopharma has overperformed the S&P 500 by 0.45% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Theravance Biopharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Theravance Biopharma has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Theravance Biopharma reported revenues of $15.4M.
Earnings Growth
-
Theravance Biopharma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Theravance Biopharma reported earnings per share of -$0.27.
Enterprise value:
451.7M
EV / Invested capital:
--
Price / LTM sales:
8.78x
EV / EBIT:
--
EV / Revenue:
6.92x
PEG ratio (5yr expected):
-0.27x
EV / Free cash flow:
13.89x
Price / Operating cash flow:
17.62x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-16.32%
Net Income Margin (TTM):
-89.38%
Return On Equity:
-31.51%
Return On Invested Capital:
-31.51%
Operating Margin:
-93.8%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $48.6M | $61.5M | $65.3M | $14.5M | $15.4M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$74.6M | -$41.2M | -$45.7M | -$11.2M | -$14.4M | |
| EBITDA | -$64.1M | -$30.3M | -$42.3M | -$8.6M | -$12.4M | |
| Diluted EPS | $11.53 | -$0.86 | -$1.18 | -$0.24 | -$0.27 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $293.1M | $204.6M | $261.3M | $124.3M | $150.3M | |
| Total Assets | $375.1M | $355.4M | $538.6M | $371.3M | $343.6M | |
| Current Liabilities | $86.5M | $44.2M | $26.2M | $21.7M | $31.5M | |
| Total Liabilities | $748.3M | $706.8M | $168M | $166.4M | $177.6M | |
| Total Equity | -$373.2M | -$351.5M | $370.6M | $204.9M | $166M | |
| Total Debt | $614.1M | $621.5M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$172.1M | -$16.8M | $32.5M | -$1M | $43M | |
| Cash From Investing | $1.1B | $27.4M | $25.9M | $17M | $30.6M | |
| Cash From Financing | -$813.6M | -$144.4M | -$1.6M | -$1.7M | -$854K | |
| Free Cash Flow | -$173.4M | -$18.4M | $32.5M | -$1.1M | $43M | |
TBPH
Sector
Market Cap
$582.5M
$34.4M
Price % of 52-Week High
98.56%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
0.48%
-1.01%
1-Year Price Total Return
16.62%
-37.36%
Beta (5-Year)
-0.018
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$11.44
200-day SMA
Buy
Level
$9.45
Bollinger Bands (100)
Buy
Level
8.89 - 10.71
Chaikin Money Flow
Buy
Level
499.6K
20-day SMA
Buy
Level
$11.06
Relative Strength Index (RSI14)
Buy
Level
65.67
ADX Line
Buy
Level
40.03
Williams %R
Sell
Level
-2.7223
50-day SMA
Buy
Level
$10.37
MACD (12, 26)
Buy
Level
3.14
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
265.1K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.0261)
Sell
CA Score
(Annual)
Level (-0.7847)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (1.3782)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Stock Forecast FAQ
In the current month, TBPH has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The TBPH average analyst price target in the past 3 months is $17.20.
-
Where Will Theravance Biopharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that Theravance Biopharma share price will rise to $17.20 per share over the next 12 months.
-
What Do Analysts Say About Theravance Biopharma?
Analysts are divided on their view about Theravance Biopharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Theravance Biopharma is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Theravance Biopharma's Price Target?
The price target for Theravance Biopharma over the next 1-year time period is forecast to be $17.20 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is TBPH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Theravance Biopharma is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of TBPH?
You can purchase shares of Theravance Biopharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Theravance Biopharma shares.
-
What Is The Theravance Biopharma Share Price Today?
Theravance Biopharma was last trading at $11.61 per share. This represents the most recent stock quote for Theravance Biopharma. Yesterday, Theravance Biopharma closed at $11.65 per share.
-
How To Buy Theravance Biopharma Stock Online?
In order to purchase Theravance Biopharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
93
EXOD alert for Jul 18
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
